Welcome to our dedicated page for Inmed Pharmaceuticals news (Ticker: INM), a resource for investors and traders seeking the latest updates and insights on Inmed Pharmaceuticals stock.
InMed Pharmaceuticals Inc. (NASDAQ: INM) is a pharmaceutical drug development company that regularly issues news and updates about its proprietary small molecule programs and related corporate activities. The company focuses on drug candidates targeting the CB1/CB2 receptors in three main therapeutic areas: Alzheimer’s disease, ocular conditions and dermatological indications, and it also reports on the commercial operations of its rare cannabinoid subsidiary BayMedica.
News about InMed often covers progress in its lead Alzheimer’s program INM-901, including preclinical data, pharmacokinetic studies in animal models and scientific presentations at major conferences such as the Alzheimer’s Association International Conference (AAIC). Releases describe how INM-901 is being evaluated across multiple biological pathways associated with Alzheimer’s disease and summarize findings from long-term studies in established disease models.
Investors and followers of INM can also find updates on INM-089, a proprietary small molecule drug candidate under investigation for dry age-related macular degeneration, including preclinical study results and formulation work for intravitreal delivery. In addition, InMed provides business updates on BayMedica, including sales performance, legislative developments affecting rare, non-intoxicating cannabinoids and the subsidiary’s evaluation of alternative supply chain options to maintain regulatory compliance.
Corporate and capital markets developments are another frequent theme in InMed’s news flow. The company announces private placements, preferred investment option amendments, participation in investor conferences, and changes to its board of directors, as well as the outcomes of its annual general and special meetings of shareholders. For readers tracking INM news, this page offers a centralized view of scientific, commercial, financial and governance announcements directly tied to the company’s disclosed activities.
InMed (NASDAQ: INM) reported Q2 FY2026 results for the quarter ended December 31, 2025 and provided a pipeline update. Key developments: INM-901 completed large-animal oral PK studies with robust bioavailability and no adverse neural effects; INM-089 showed functional improvements in dry AMD models. Financials: cash of $7.0M, Q2 net loss of $2.03M, BayMedica revenue down 26% YoY to $0.8M. The company expects cash to fund operations into Q4 calendar 2026 and flagged material legislative risk from H.R. 5371 affecting BayMedica.
InMed Pharmaceuticals (NASDAQ: INM) reported results from its annual general and special meeting held December 17, 2025.
A total of 993,491 common shares (≈35.43% of 2,804,186 outstanding) were represented. All five director nominees were elected with roughly 81.9%–82.1% votes for. Shareholders approved CBIZ CPAs P.C. as auditors and approved the potential issuance of 20% or more of common shares under the amended Standby Equity Purchase Agreement with YA II PN, Ltd. The company filed the voting results on SEDAR+ on December 17, 2025.
InMed (NASDAQ: INM) said on December 12, 2025 that provisions in H.R. 5371 (the "Act") could materially and negatively affect the commercial business of subsidiary BayMedica if those provisions come into force on November 12, 2026.
The company said the Act in its current form would prohibit certain aspects of BayMedica's commercial operations and its inventory of rare, non‑intoxicating cannabinoids, and that BayMedica is evaluating alternative supply‑chain options while continuing normal operations.
InMed emphasized the Act does not affect its core pharmaceutical programs and reaffirmed progress on INM‑901 for Alzheimer's disease and INM‑089 for age‑related macular degeneration. The company noted uncertainty whether the relevant Act provisions will take effect or be amended and pointed investors to its SEC filings for details on BayMedica's contribution to consolidated results.
InMed (NASDAQ: INM) reported Q1 fiscal 2026 results for the quarter ended September 30, 2025 and provided a business update on its drug programs.
Key metrics: cash and cash equivalents $9.3M (down from $11.1M June 30, 2025), BayMedica revenue $1.12M (down 11% year-over-year), R&D $0.58M, and net loss $1.73M. Management expects cash to fund operations into Q4 calendar 2026 depending on revenues and expense timing.
Program highlights: INM-901 advanced preclinical work with a 7-month 5xFAD mouse study presented at AAIC and IND-enabling and CMC activities underway; INM-089 continues preclinical evaluation for dry AMD.
InMed Pharmaceuticals (NASDAQ: INM) announced the immediate appointment of John Bathery to its Board of Directors, effective October 16, 2025.
Bathery brings more than 30 years of pharmaceutical experience, including 15+ years in corporate development, and has led transactions exceeding $60 billion. The company said his expertise will support advancement of INM-901 for Alzheimer’s and INM-089 for age-related macular degeneration toward clinical readiness and partnership exploration.
The release also said Bryan Baldasare will not stand for re-election at the December 18, 2025 annual meeting.
InMed Pharmaceuticals (NASDAQ: INM) appointed Neil Klompas, CPA, CA to its board effective October 9, 2025.
Klompas brings 30+ years of healthcare and biotech experience, including roles as President and COO and earlier CFO at Zymeworks, where he helped scale the company and led its 2017 IPO. He is currently CEO of Augerex Life Science and serves on the boards of NervGen Pharma and HTuO Biosciences. InMed highlighted Klompas’ operational, financial and capital-markets expertise as supportive for advancing its pipeline; Klompas praised InMed's science and cited INM-901 data as a draw.
InMed Pharmaceuticals (NASDAQ: INM) reported its fiscal year 2025 financial results and provided updates on its pharmaceutical pipeline. The company recorded $4.9M in revenue (8% YoY increase) and a net loss of $8.2M. Cash position stands at $11.1M, sufficient to fund operations into Q4 2026.
Key developments include advancement of INM-901 for Alzheimer's disease, demonstrating significant reductions in neuroinflammation and improved cognitive outcomes in preclinical studies. The company also progressed with INM-089 for dry age-related macular degeneration, showing promising neuroprotective results.
Research and development expenses were $2.9M, down from $3.2M in 2024, while general and administrative expenses increased to $6.6M from $5.8M in the previous year.
[ "Cash position of $11.1M provides runway into Q4 2026", "BayMedica revenue increased 8% YoY to $4.9M", "INM-901 showed statistically significant reductions in neuroinflammation markers", "Successful oral administration of INM-901 achieving therapeutic brain levels", "R&D expenses decreased from $3.2M to $2.9M year-over-year" ]InMed Pharmaceuticals (NASDAQ: INM) announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference in New York. The company's Chief Operating Officer, Michael Woudenberg, will deliver a corporate presentation highlighting updates on InMed's pipeline, including recent data from their leading pharmaceutical program INM-901 for Alzheimer's treatment.
The presentation will be available via webcast for 90 days, and InMed's management team will conduct one-on-one meetings with investors during the conference. The recent data from INM-901 was previously presented at the Alzheimer's Association International Conference (AAIC) 2025.
InMed Pharmaceuticals (NASDAQ: INM) announced the presentation of new preclinical data for its INM-901 drug candidate at the upcoming Alzheimer's Association International Conference (AAIC) 2025 in Toronto. The study evaluated INM-901's long-term treatment effects in a 5xFAD mouse model of advanced Alzheimer's disease.
The research demonstrated that INM-901 showed multiple positive effects, including: reduction in inflammatory biomarkers, decreased amyloid-beta immunoreactivity, partial restoration of MAP2 protein, and improvements in cognitive function. The drug candidate exhibited dose-dependent therapeutic effects in neuroinflammation and showed promise in restoring behavioral and sensory responses to normal levels.
The data will be presented in a scientific poster titled "Therapeutic Potential of INM-901 in Mitigating Alzheimer's Disease Pathology: Insights from a Long-term 5xFAD Mouse Model Study" at AAIC 2025, scheduled for July 27-31.
InMed Pharmaceuticals (NASDAQ: INM) has closed a private placement offering, raising $5 million through the sale of 1,952,363 common shares (or pre-funded warrants) at $2.561 per share. The offering includes short-term preferred investment options exercisable at $2.436 per share, which could generate an additional $4.75 million if fully exercised.
The company plans to use the proceeds for pipeline development of pharmaceutical drug candidates, support commercial sales through BayMedica LLC subsidiary, and general working capital. Additionally, InMed amended existing preferred investment options from October 2023, reducing the exercise price from $16.60 to $2.436 per share.